EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) are superior to cytotoxic chemotherapy in terms of efficacy and have become the standard treatment option for patients with EGFR‐mutant NSCLC.4, 5, 6